JAK1 阻害薬であるフィルゴチニブは, 関節リウマチに関連するバイオマーカーを調節する: 2つのランダム化対照フェーズ2b試験結果
Rheumatol Ther. 2020 DOI: 10.1007/s40744-019-00192-5
In this study examining the effect of FIL on a panel of biomarkers, FIL down-modulated several key inflammatory mediators of signalling pathways in RA - independent of MTX background therapy. This confirmed the strong network effects of the JAK1 node in autoimmunity, matrix and cartilage degradation, angiogenesis, and leukocyte adhesion and recruitment. Biomarkers key to RA pathophysiology were measured at baseline, Wk4 and Wk12 in FIL 100 mg, FIL 200 mg or PBO treatment groups from two phase 2b...